SER-109, an Investigational Microbiome Drug to Reduce Recurrence After Clostridioides difficile Infection: Lessons Learned From a Phase 2 Trial

by Cyrus Huneycutt | Sep 21, 2023 | 0 comments

Submit a Comment Cancel reply

You must be logged in to post a comment.